Shepherd Street Advisors LLC Invests $1.36 Million in Vertex Pharmaceuticals Incorporated $VRTX

Shepherd Street Advisors LLC purchased a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the fourth quarter, Holdings Channel reports. The fund purchased 2,995 shares of the pharmaceutical company’s stock, valued at approximately $1,358,000. Vertex Pharmaceuticals makes up about 1.3% of Shepherd Street Advisors LLC’s investment portfolio, making the stock its 27th biggest position.

A number of other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Vertex Pharmaceuticals by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 24,216,865 shares of the pharmaceutical company’s stock worth $9,484,293,000 after buying an additional 243,088 shares during the last quarter. Capital Research Global Investors increased its holdings in shares of Vertex Pharmaceuticals by 2.8% in the 3rd quarter. Capital Research Global Investors now owns 16,553,281 shares of the pharmaceutical company’s stock worth $6,482,978,000 after buying an additional 444,990 shares during the last quarter. Capital International Investors increased its holdings in shares of Vertex Pharmaceuticals by 77.9% in the 3rd quarter. Capital International Investors now owns 4,689,059 shares of the pharmaceutical company’s stock worth $1,836,550,000 after buying an additional 2,053,156 shares during the last quarter. Alliancebernstein L.P. increased its holdings in shares of Vertex Pharmaceuticals by 3.3% in the 3rd quarter. Alliancebernstein L.P. now owns 4,522,586 shares of the pharmaceutical company’s stock worth $1,771,226,000 after buying an additional 144,266 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth $1,440,149,000. Institutional investors own 90.96% of the company’s stock.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Joy Liu sold 1,104 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $425.02, for a total value of $469,222.08. Following the sale, the executive vice president directly owned 20,729 shares in the company, valued at approximately $8,810,239.58. This trade represents a 5.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 6,988 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $450.00, for a total value of $3,144,600.00. Following the completion of the sale, the chief marketing officer owned 26,088 shares in the company, valued at approximately $11,739,600. This represents a 21.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 11,717 shares of company stock worth $5,309,945. 0.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on VRTX shares. Jefferies Financial Group started coverage on shares of Vertex Pharmaceuticals in a report on Tuesday, March 10th. They issued a “buy” rating and a $580.00 price target on the stock. Morgan Stanley upped their price objective on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the company an “overweight” rating in a research note on Tuesday, May 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $590.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday, February 13th. Wall Street Zen cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings raised shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, May 18th. Twenty-two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $555.91.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex announced that the FDA accepted its Biologics License Application for povetacicept in adults with IgA nephropathy, putting the drug on track for a November 30, 2026 decision date. If approved, this could become Vertex’s first commercial nephrology product and help diversify the business beyond cystic fibrosis. Article Title
• Positive Sentiment: Vertex also received recognition for JOURNAVX, which was named a Premier, Inc. Breakthroughs Innovation Celebration winner, adding another positive headline for its pain franchise. Article Title
• Neutral Sentiment: Several recent commentary pieces highlighted that Vertex remains a high-quality cash-flow generator with a strong cystic fibrosis franchise, but also noted that the stock has been consolidating and is being watched closely for whether it offers a better entry point. Article Title
• Neutral Sentiment: Analyst coverage remained supportive, with reports saying Wall Street is still broadly optimistic about Vertex despite recent underperformance versus the healthcare sector. Article Title
• Negative Sentiment: Recent trading has reflected some investor caution after JOURNAVX and Casgevy sales missed expectations, and Vertex stock has been under pressure over the past few months even though its cystic fibrosis business and renal pipeline remain intact. Article Title

Vertex Pharmaceuticals Stock Down 3.0%

Shares of VRTX opened at $425.09 on Wednesday. The stock has a market capitalization of $107.89 billion, a P/E ratio of 25.21, a PEG ratio of 1.88 and a beta of 0.30. The firm has a fifty day simple moving average of $438.67 and a two-hundred day simple moving average of $451.92. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $507.92.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.24 by $0.23. The business had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $2.99 billion. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.06 EPS. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 16.99 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.